Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

2.1 Pembrolizumab (Keytruda, MSD) has a marketing authorisation in the UK 'as monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least 2 prior therapies when ASCT is not a treatment option'.

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.3 The list price is £2,630 for 1 × 100 mg vial (excluding VAT; BNF online accessed December 2021).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.